The Acetazolamide Challenge: Imaging Techniques Designed to Evaluate Cerebral Blood Flow Reserve

Cerebral blood flow was analyzed by the stable xenon (Xe)/CT scanning technique in 29 patients with significant vascular lesions before and after administration of an acetazolamide (Diamox) vasodilatory challenge. Three response types were identified: I, normal flow before Diamox with flow augmentation after Diamox; II, low flow before Diamox with flow augmentation after Diamox; and III, low or normal flow before Diamox with no augmentation or decreased flow after Diamox. Twenty-four percent of the patients studied qualified for category III. We believe that patients in this category represent a group of individuals without blood flow reserve whose clinical management should include careful consideration of their hemodynamic status.

The Xe/CT scanning technique with the addition of Diamox flow challenge is a clinically accessible and effective method for assessing cerebral blood flow and blood flow reserve.

The development of a clinically accessible means to identify patients with neurologic symptoms caused by transient focal or global low cerebral blood flow (CBF) has important potential therapeutic implications [1–3]. Signs and symptoms of decreased cerebrovascular reserves and episodic low CBF are generally nonspecific and may be difficult to recognize [4]. Angiography is imprecise in establishing the diagnosis because this technology is unable to provide the physiologic information necessary to assess the adequacy of primary or collateral regional blood supply [5]. Ideally, this analysis is performed by positron emission tomography (PET), which requires the measurement of both CBF and metabolism [6, 7]. PET is, however, available at relatively few centers. This article describes the use of stable xenon (Xe)/CT performed before and after a vasodilatory challenge to identify patients with low cerebral blood flow and blood flow reserve.

The strategy we followed was derived in part from PET studies that determined that the cerebral arteries maintain CBF in response to decreased perfusion pressure by dilatation [2]. After vessels are maximally dilated, any further compromise in perfusion pressure results in a progressive decrease in blood flow and an accompanying increase in oxygen extraction. When this condition, termed “misery perfusion” [3], has been achieved, additional vasodilatory challenges would not be expected to augment flow. When CBF falls below 20 ml/100 g/min in normal cortical tissue, metabolism and neurologic function become compromised as the regional oxygen and glucose supply to the brain is expended [8, 9].

Although local cerebral blood flow values may be reduced by proximal vascular compromise and inadequate supply, CBF can also be reduced by decreased metabolic demand caused by either neuronal loss or deafferentation. Therefore, a single measurement of CBF, regardless of the method—Xe-133, single photon emission CT (SPECT), or stable Xe/CT—does not give nonspecific information in this regard. However, the addition of a second measurement obtained during a vasodilatory challenge can assess whether territorial reserves have been compromised. That is, CBF augmentation would not be expected in regions that already

This article appears in the July/August 1989 issue of AJNR and the September 1989 issue of AJR.

Received June 24, 1988; revision requested August 22, 1988; revision received November 11, 1988; accepted December 5, 1988.

1 Department of Radiology, Brown University School of Medicine, Providence, RI 02902.
2 University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
3 Department of Radiology and Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213. Address reprint requests to H. Yonas.
4 Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
5 AJNR 10:803–810, July/August 1989
0195-6108/89/1004-0803
© American Society of Neuroradiology
<table>
<thead>
<tr>
<th>Case No.</th>
<th>Clinical History</th>
<th>Significant Vascular Anatomy</th>
<th>Age</th>
<th>Pre-pCO₂/Post-pCO₂</th>
<th>Baseline Cerebral Blood Flow</th>
<th>Xe Diamox</th>
<th>Type*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>L hemiparesis expressive aphasia</td>
<td>R MCA occlusion</td>
<td>59</td>
<td>39/30</td>
<td>Focal R MCA distr.; low flow</td>
<td>No change</td>
<td>III</td>
</tr>
<tr>
<td>2</td>
<td>L facial and upper extremity weakness; symptoms related to decreased blood pressure</td>
<td>R ICA occlusion; bilateral moderate VA stenosis</td>
<td>78</td>
<td>38/30</td>
<td>Diffuse low</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>3</td>
<td>Transient L hemisphere symptoms</td>
<td>L ICA occlusion</td>
<td>55</td>
<td>31/27</td>
<td>Focal L ICA distr.; low flow</td>
<td>No change</td>
<td>III</td>
</tr>
<tr>
<td>4</td>
<td>L hemisphere TIAs after endarterectomy</td>
<td>R &amp; L VA stenosis</td>
<td>50</td>
<td>39/37</td>
<td>Normal</td>
<td>Diffuse increase</td>
<td>I</td>
</tr>
<tr>
<td>5</td>
<td>L TIA</td>
<td>R &amp; L VA stenosis</td>
<td>57</td>
<td>42/40</td>
<td>Focal L MCA decreased flow</td>
<td>Unchanged</td>
<td>III</td>
</tr>
<tr>
<td>6</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>&gt;80% L ICA stenosis</td>
<td>66</td>
<td>34/24</td>
<td>Normal</td>
<td>Diffuse increase</td>
<td>I</td>
</tr>
<tr>
<td>7</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>&gt;80% L ICA stenosis; &gt;80% L subclavian stenosis; R subclavian occlusion</td>
<td>66</td>
<td>34/24</td>
<td>Normal</td>
<td>Diffuse increase</td>
<td>I</td>
</tr>
<tr>
<td>8</td>
<td>L carotid bruit Doppler 80% L ICA stenosis</td>
<td>&gt;70% L ICA stenosis</td>
<td>66</td>
<td>34/24</td>
<td>Normal</td>
<td>Diffuse increase</td>
<td>I</td>
</tr>
<tr>
<td>9</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L occipital infarct; light-headedness</td>
<td>54</td>
<td>42/34</td>
<td>Normal</td>
<td>Diffuse increase</td>
<td>I</td>
</tr>
<tr>
<td>10</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>R ICA occlusion</td>
<td>63</td>
<td>30/26</td>
<td>Low flow R ACA; R MCA distr. (perifarct)</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>11</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>R ICA occlusion</td>
<td>60</td>
<td>36/30</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>12</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>R ICA occlusion</td>
<td>66</td>
<td>30/27</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>13</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L ICA occlusion</td>
<td>67</td>
<td>41/38</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>14</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L ICA occlusion</td>
<td>60</td>
<td>30/27</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>15</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L ICA occlusion</td>
<td>66</td>
<td>30/27</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>16</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L ICA occlusion</td>
<td>67</td>
<td>41/38</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>17</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L ICA occlusion</td>
<td>60</td>
<td>36/30</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>18</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L ICA occlusion</td>
<td>66</td>
<td>30/27</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>19</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L ICA occlusion</td>
<td>67</td>
<td>32/28</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>20</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L ICA, R ICA, R VA occlusion; L EC-IC bypass</td>
<td>70</td>
<td>41/38</td>
<td>Normal</td>
<td>Diffuse increase</td>
<td>I</td>
</tr>
<tr>
<td>21</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L ICA occlusion</td>
<td>66</td>
<td>30/27</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>22</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L ICA occlusion</td>
<td>67</td>
<td>32/28</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>23</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L ICA occlusion</td>
<td>67</td>
<td>32/28</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
<tr>
<td>24</td>
<td>Transient R hemiparesis &amp; expressive aphasia</td>
<td>L ICA occlusion</td>
<td>67</td>
<td>32/28</td>
<td>Global low flow</td>
<td>Diffuse increase</td>
<td>II</td>
</tr>
</tbody>
</table>
Table 1—Continued

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Clinical History</th>
<th>Significant Vascular Anatomy</th>
<th>Age</th>
<th>Pre-pCO₂/Post-pCO₂</th>
<th>Baseline Cerebral Blood Flow</th>
<th>Xe Diamox</th>
<th>Type*</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>Vertigo</td>
<td>Doppler; R ICA stenosis</td>
<td>62</td>
<td>32/32</td>
<td>Diffuse low flow</td>
<td>Focal low</td>
<td>III</td>
</tr>
<tr>
<td>26</td>
<td>L carotid bruit</td>
<td>90% L ICA stenosis</td>
<td>69</td>
<td>Normal</td>
<td>Diffuse increase</td>
<td>I</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>R amaurosis fugax</td>
<td>L ICA &amp; R ICA occlusion; 80% L VA stenosis; 60% R VA stenosis</td>
<td>63</td>
<td>Diffuse low flow</td>
<td>Diffuse increase</td>
<td>II</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>L bruit; old MCA infarct</td>
<td>99% L ICA stenosis; 50% R ICA stenosis</td>
<td>42</td>
<td>Focal low flow (perifaction)</td>
<td>Diffuse increase</td>
<td>II</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>L upper extremity weakness</td>
<td>99% R ICA stenosis; L ICA occlusion; 50% L &amp; R VA stenosis</td>
<td>55</td>
<td>Normal</td>
<td>Focal decrease (R ICA distr.)</td>
<td>III</td>
<td></td>
</tr>
</tbody>
</table>

* Type: I = normal baseline with post-Diamox flow augmentation; II = low-flow baseline with post-Diamox augmentation; III = low or normal baseline with no response or decreased flow post-Diamox. Low = 20–35, normal = 35–60, high = >60 (as defined in text).

Note.—ACA = anterior cerebral artery; MCA = middle cerebral artery; PCA = posterior cerebral artery; subclav = subclavian artery; VA = vertebral artery; ICA = internal carotid artery; R = right; L = left; EC-IC = extracranial to intracranial; TIA = transient ischemic attack; CVA = cerebrovascular accident.

have maximum vasodilation, while augmentation would be expected in regions with reduced CBF secondary to decreased metabolic demand.

On the basis of this theory, some investigators have measured CBF before and after a flow challenge to identify patients with "misery perfusion." Various methods have been used to create a flow challenge: (1) elevating or lowering blood pressure, (2) having patients inhale a 3–5% carbon dioxide mixture, or, more recently, (3) administering an IV acetazolamide (Diamox) bolus [9–12].

Acetazolamide is easy to administer, safe, and provokes a predictably potent vasodilatory challenge [13–15]. The specific action of the drug that causes vasodilation is unclear, but it is believed that vasodilation is mediated by the drug's inhibition of carbonic anhydrase [12, 13]. The vasodilatory effect appears to be localized to the brain [13, 15, 16], and the activity of the drug remains potent despite baseline increased tissue levels of pCO₂ [13, 14]. The degree of CBF augmentation found in the normal individual has ranged from 70–90% [12, 13]. With advancing age, activated flows may not increase as dramatically, but flow symmetry will remain preserved [12].

Materials and Methods

CBF was determined by the Xe/CT CBF method. The Xe/CT method is a relatively new CBF technology that provides tomographic, quantitative CBF information with direct anatomic correlation.* This methodology has been addressed in detail previously [1, 17–19]. Xe/CT CBF with an acetazolamide challenge can be performed on an outpatient as well as inpatient basis. The average time to complete a double CBF study—before and 20 min after the administration of acetazolamide—is 60 to 90 min. Patient cooperation is required for this study, which also demands direct involvement of a health care professional. Immediately after the initial CBF study, 1 g of IV acetazolamide is administered. The second study is begun 20 min after drug delivery. Typically, acetazolamide results in a reduction of measured end tidal CO₂ (see Table 1) without alteration of vital signs or other associated symptoms.

We studied 29 patients with significant vascular disease diagnosed by either noninvasive studies or angiography. Twenty-three individuals had at least one significantly stenosed or occluded carotid artery, and 12 had occlusion in two or more major vessels (Table 1). Three patients were asymptomatic and underwent these studies because they were found to have a carotid bruit. Twenty-six patients had experienced transient ischemic attacks (TIAs) or fixed neurologic compromise. The latter patients were studied at least 3 weeks after a stroke. This allowed time for the recoupling of CBF and metabolism to occur.

* General Electric Medical Systems, Milwaukee, WI.
We compared pre- and postacetazolamide CBF studies by using standard contrast-mode software and region-of-interest density software for blood flow analysis (see Fig. 1). In the contrast mode, all values above the designated flow level are displayed as white, and all values below as black (see Figs. 2E and 2F). Regions of interest for regional cerebral blood flow (rCBF) were consistent with vascular territories reported by Damasio [20]. Pre- and postacetazolamide blood flow maps were compared for evidence of flow change in corresponding vascular territories. We generally considered rCBF to be within normal limits when flows ranged between 35 and 60 ml/100 g/min. Acceptable limits of normal were somewhat dependent on patient age, however, as flows of 35 ml/100 g/min were considered low in a 20-year-old but acceptable in an 80-year-old. An rCBF between 20 and 35 was generally considered low; an rCBF greater than 60 was generally considered elevated.

**Results**

The results are summarized in Table 1. This table provides clinical information and significant vascular anatomy for each of the 29 patients in the study. All patients had at least one major vessel with greater than 50% stenosis. Twelve (41%) had multivessel disease. pCO₂ values are provided to demonstrate that Diamox was physiologically active, blocking carbonic anhydrase and thereby decreasing pCO₂ in all cases.

Three basic types of responses to Diamox are defined: type I, normal CBF before Diamox with flow augmentation after Diamox; type II, diffuse or focal low CBF before Diamox with augmentation after Diamox; type III, low or normal CBF before Diamox with no response or decreased CBF after Diamox. Thirteen patients (45%) had a type I response, nine patients (31%) had a type II response, and seven patients (24%) had a type III response. The following four cases are representative of each response type and are described in greater detail in Table 2.

Type I (case 26, Table 1): A 69-year-old man was evaluated after being diagnosed, during a routine physical examination, as having an asymptomatic left carotid bruit. Noninvasive studies showed severe stenosis of his left internal carotid artery (ICA). Angiography confirmed 80–90% stenosis at the origin of the proximal left ICA; the remainder of the intracranial vasculature and the circle of Willis were normal. A CT scan (Fig. 1A) was unremarkable, and the baseline Xe/CT CBF study (Fig. 1B) was normal. Flow was symmetrical in all territories, with most values ranging between 45 and 55 ml/100 g/min. Twenty minutes after the patient received 1 g of IV acetazolamide, we performed a second CBF study (Fig. 1C), which showed an average flow increase of 36% in all vascular territories (Table 2).

Type II (case 27, Table 1): A 63-year-old woman presented with a sudden onset of blindness in the right eye that resolved partially over the next 6 weeks. Angiography demonstrated 90% stenosis at the origin of the left common carotid artery and occlusion of the left internal carotid artery (ICA). The right ICA also was occluded, and the right external carotid artery was moderately stenotic at its origin. The origin of the left vertebral artery had an 80% stenosis, and the origin of the right vertebral artery had 50–60% stenosis. Collateral supply to the right ICA siphon was supplied by ethmoidal vessels. In addition to flow from the right ICA, the right anterior cerebral artery (ACA) and middle cerebral artery (MCA) also received collateral flow through the right posterior communicating artery and leptomeningeal collaterals from the right posterior cerebral distributions. The baseline Xe/CT CBF study demonstrated lower flow values bilaterally than would be expected in a 63-year-old person (a mean of 29, Table 2). The introduction of acetazolamide, however, caused a symmetrical flow augmentation of 55% (up to 44.9 ml/100 g/min).

Type II (case 28, Table 1): A 42-year-old man presented with an asymptomatic bruit found after a significant left hemi-

---

Fig. 1.—A-C, Case 26. Xe/CT scans demonstrate a representative type I normal scan series. 
A. The middle of the usual three levels selected for evaluation.  
B. Baseline Xe/CT image with superimposed vascular territory map and region of interest blood flows (ml/100 g/min).  
C. Repeat Xe/CT CBF evaluation after Diamox (1 g IV). Flow augmentation has occurred in all vascular territories.
sphere, closed head injury. His examination revealed a mild residual expressive aphasia. CT images disclosed an area of encephalomalacia in the left middle cerebral artery distribution, consistent with a remote infarction (Fig. 2A). Angiography demonstrated 99% stenosis at the origin of the left ICA and 50% stenosis at the origin of the right ICA. Collateral flow to the left hemisphere occurred by retrograde ophthalmic artery flow to the carotid siphon, and by posterior communicating artery and leptomeningeal collaterals from the posterior circulation. The baseline Xe/CT CBF study showed an area of hypoperfusion corresponding to the site of previous infarction, but also showed compromised flow values in the remainder of the left middle cerebral artery (Figs. 2B, 2E, and Table 2). After receiving 1 g of acetazolamide, there was an increase of CBF in all territories, including the region immediately posterior to the infarction within the distal distribution of the middle cerebral artery (Figs. 2C, 2F, and Table 2).

Type III (case 29, Table 1): A 55-year-old man presented with left upper extremity weakness and left facial paresis of recent onset. An angiogram defined a 95% stenosis at the proximal right ICA, and complete occlusion of the left ICA. The left and right anterior and middle cerebral arteries were supplied by the stenotic right ICA. The left middle cerebral artery was supplied by collateral vessels from the left external

---

Fig. 2.—A–F, Case 28. Xe/CT scans demonstrate a representative type II scan series. A shows an area of encephalomalacia in left frontoparietal region from a previous infarction. The level above, D, appears normal. In B and E, Xe/CT shows that the area of decreased CBF is greater than that expected from plain CT. Flows are decreased in the left frontal and midparietal regions anterior and posterior to the old infarction, as well as in the frontoparietal region above the site of the infarct. In C and F, Post-Diamox flow augmentation is seen in perinfarct zone at level of, and cephalad to, the known area of encephalomalacia. E and F were filmed at a level of 20 (white = flow greater than 20 ml/100 g/min) to accentuate flow differences before and after Diamox.
carotid and left posterior cerebral arteries. The origins of both vertebral arteries were moderately stenotic. A CT scan was unremarkable (Fig. 3A). The baseline Xe/CT CBF study disclosed normal baseline flow values within all territories, but with mild asymmetry (R < L) (Figs. 3B, 3C, and Table 2). After the addition of acetazolamide, flow remained unchanged or decreased in all right anterior circulation territories and in the left anterior cerebral artery territory (Figs. 3D, 3E, and Table 2).

Discussion

The diagnostic utility and specificity provided by the use of acetazolamide as a vasodilatory challenge were suggested by Vorstrup et al. [21], who used Xe-133 with SPECT imaging to evaluate patients before and after extracranial-intracranial bypass operations [21, 22]. These researchers noted postoperative augmentation of resting CBF in only one of the 13 patients with preoperative regional hypoperfusion; this patient was also the only patient in the study whose CBF was not increased after preoperative acetazolamide flow challenge. These findings support the contention that acetazolamide flow challenge can identify those patients who already have maximal vasodilation and minimal flow reserves.

On the basis of our experience, we defined three types of responses to an acetazolamide challenge: I, an increase in normal baseline flow values; II, an increase in focal or diffuse low flow values; and III, no change or a decrease in low or normal flow values. Type III is the only group that would
include the single patient reported by Vorstrup et al. [21] and the group with "misery perfusion" reported by Baron et al. [3]. Each of these categories is represented by one or two of the cases described earlier. Case 26 is an example of type I: normal baseline CBF that increased significantly after the administration of acetazolamide. This patient is typical of many patients (13 of 29) we studied who had normal flow despite angiographic evidence of significant stenosis or occlusion.

Cases 27 and 28 exemplify type II: diffuse or focal low flow in baseline studies but with maintained reserves of CBF as demonstrated by the ability to augment flow with acetazolamide. Nine of our 29 patients fell into this group. Although angiography suggested that the supply of blood was severely compromised in case 27, the patient’s retention of metabolism, despite the decreased CBF, suggested that the low flow areas were appropriate to the decreased demand. The patient’s absence of further symptoms while on anticoagulation therapy in the 6 months following this assessment supports our assumption of an embolic origin of her symptoms.

Case 28 illustrates reduced CBF, and presumably reduced metabolism, due to deafferentation. Figure 2B shows a region with relatively low flow posterior to the CT-defined infarction, despite the relatively normal appearance of this region on the CT images. After acetazolamide administration, the flow in this area increased, providing evidence for adequate availability of blood flow, but reduced demand. The presence of a larger area of flow and metabolic disturbance than suggested by the CT-defined injury has been widely reported [23].

Case 29 represents type III, low or normal baseline flow values that decreased in a potentially compromised vascular distribution after the patient received acetazolamide, despite an elevation of CBF in other areas. This finding suggested that there is little potential for collateral flow to the portion of the brain that angiography has shown to be supplied preferentially by the right ICA. If the right ICA were further compromised, the patient would be at a significant risk of sustaining a massive stroke [24]. The patient was scheduled for emergency right carotid endarterectomy but before this could be performed, 36 hr after the study, the predictive value of the acetazolamide challenge was substantiated by the onset of a massive stroke in the territory of the right middle cerebral artery (Fig. 3F). Seven (24%) of our 29 patients with significant occlusive vascular disease were in this category.

Despite angiographic and/or noninvasive evidence of significant occlusive vascular disease, 76% of the patients studied by Xe/CT CBF had, at rest, flow values that increased significantly with acetazolamide. This finding is consistent with earlier reports that emphasize the imprecision of existing anatomic methods for predicting hemodynamic compromise [5], and is supported by Sullivan et al. [13], who found that 40% of patients with significant vascular disease on angiography had normal CBF when given an acetazolamide flow challenge and studied by Xe-133 scintillation counting. The studies of Vorstrup and others along with our own limited experience indicate that patients who have type III responses are those most likely to benefit from medical or surgical efforts to augment CBF delivery.

Although the international study of extracranial-intracranial bypass operations suggested that flow augmentation procedures were not of significant clinical benefit [25, 26], a recent review of that study suggests that a subgroup of critically flow-dependent patients may have been excluded [27]. Our experience indicates that the Xe/CT CBF technique combined with a challenge of flow reserve is a useful clinical means to identify a hemodynamically compromised subgroup of individuals who may have transient symptoms due to a marginal basal level of perfusion that transiently drops to a level inadequate to maintain function. Once such persons are identified, future studies are needed to define their prognosis and determine whether they may benefit from either medical or surgical approaches.

In summary, we believe that Xe/CT CBF measurements used with an acetazolamide challenge provide an objective, clinically accessible method of assessing cerebral blood flow and blood flow reserve.

REFERENCES